技術(shù)背景
2022年空間多組學(xué)技術(shù)被Nature評(píng)為七大“顛覆性”技術(shù)之一,是將基因組、轉(zhuǎn)錄組、蛋白質(zhì)組以及代謝組的檢測(cè)結(jié)果與組織原位信息相結(jié)合,重塑空間立體結(jié)構(gòu)內(nèi)相關(guān)組學(xué)信息的定位分布情況。隨著多個(gè)免疫治療藥物的獲批,腫瘤免疫療法日趨成熟,人們?cè)絹?lái)越多地關(guān)注組織微環(huán)境的概念及其在腫瘤免疫治療中的作用。腫瘤細(xì)胞可以通過(guò)釋放細(xì)胞外信號(hào)影響周邊的微環(huán)境,促進(jìn)腫瘤血管增生和抑制周邊的免疫細(xì)胞,而腫瘤微環(huán)境中的免疫細(xì)胞及因子又可以影響腫瘤細(xì)胞的生長(zhǎng)(見(jiàn)下圖)。

服務(wù)內(nèi)容
空間多組學(xué)技術(shù)眾多,從高通量空間轉(zhuǎn)錄組和蛋白組到低通量RNA原位檢測(cè)技術(shù)和多重?zé)晒饷庖呓M化技術(shù),不同方法學(xué)在各自應(yīng)用領(lǐng)域發(fā)揮著獨(dú)特的作用。菲諾維康擁有完整的空間多組學(xué)平臺(tái),集研發(fā)、實(shí)驗(yàn)室服務(wù)以及臨床應(yīng)用開(kāi)發(fā)于一體,提供多組學(xué)(DNA\RNA\蛋白)一站式空間生物學(xué)解決方案。

應(yīng)用方向

案例展示
空間表型分析可以將標(biāo)記物組合(panel)分為幾大類:鑒別T細(xì)胞及其亞型(如殺傷性T細(xì)胞、輔助型T細(xì)胞)在腫瘤中的分布;鑒別M1型/M2型巨噬細(xì)胞在腫瘤中的分布;聚焦B細(xì)胞不同亞型(如CD20,CD21為代表的B細(xì)胞亞型)以及三級(jí)淋巴結(jié)構(gòu)在腫瘤中的分布;關(guān)注更多種免疫細(xì)胞類型,如將NK細(xì)胞、樹(shù)突細(xì)胞引入到panel中,觀察不同免疫細(xì)胞在腫瘤中的分布;聚焦結(jié)合腫瘤標(biāo)記物以及免疫檢測(cè)點(diǎn),觀察不同幾大細(xì)胞類型(腫瘤細(xì)胞、B細(xì)胞、T細(xì)胞、巨噬細(xì)胞等)在腫瘤中的分布。

人腸癌組織

人乳腺癌組織

人黑色素瘤組織

人肺癌組織
參考文獻(xiàn)
- Lu S, Stein JE, Rimm DL, et al. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(8):1195-1204. doi:10.1001/jamaoncol.2019.1549.
- Gao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 Dec;26(12):1845-1851. doi: 10.1038/s41591-020-1086-y. Epub 2020 Oct 12.
- Park, Y.H., Lal, S., Lee, J.E. et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun. 2020 Dec 2;11(1):6175.doi: 10.1038/s41467-020-19933-0.
- Biswas S, Mandal G, Payne KK, et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021 Mar;591(7850):464-470. doi: 10.1038/s41586-020-03144-0. Epub 2021 Feb 3. PMID: 33536615.
- Berry S, Giraldo NA, Green BF, et al. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science. 2021 Jun 11;372(6547):eaba2609. doi: 10.1126/science.aba2609. PMID: 34112666.
- Hoyt CC. Multiplex Immunofluorescence and Multispectral Imaging: Forming the Basis of a Clinical Test Platform for Immuno-Oncology. Front Mol Biosci. 2021 Jun 2;8:674747. doi: 10.3389/fmolb.2021.674747.
- Taube JM, Roman K, Engle EL, et al. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. J Immunother Cancer. 2021 Jul;9(7):e002197. doi: 10.1136/jitc-2020-002197.
- Vanhersecke L, Brunet M, Guégan JP, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021 Aug;2(8):794-802. doi: 10.1038/s43018-021-00232-6. Epub 2021 Aug 12.
- Anadon CM, Yu X, Hänggi K, et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May 9;40(5):545-557.e13. doi: 10.1016/j.ccell.2022.03.008. Epub 2022 Apr 14.
- Attrill GH, Owen CN, Ahmed T, et al. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. J Immunother Cancer. 2022 Jun;10(6):e004771. doi: 10.1136/jitc-2022-004771.
- Melero I, Villalba-Esparza M, Recalde-Zamacona B, et al. Neutrophil Extracellular Traps, Local IL-8 Expression, and Cytotoxic T-Lymphocyte Response in the Lungs of Patients With Fatal COVID-19. Chest. 2022 Nov;162(5):1006-1016. doi: 10.1016/j.chest.2022.06.007. Epub 2022 Jun 15.
- Liu Z, Zhao Y, Kong P, et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell. 2023 Jan 9;41(1):181-195.e9. doi: 10.1016/j.ccell.2022.12.004. Epub 2022 Dec 29.
- Yang S, Qian L, Li Z, et al. Integrated Multi-Omics Landscape of Liver Metastases. Gastroenterology. 2023 Mar;164(3):407-423.e17. doi: 10.1053/j.gastro.2022.11.029. Epub 2022 Nov 26.